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Abstract 
A novel thermal rearrangement, involving pyrimidine ring opening and subsequent ring closure 
leading to recyclization of the system, was identified in the reaction of (6-oxo-1,6-




= NH2, NH alkyl, NH aralkyl, NHCH2Ph(R)) 
with triethyl orthoacetate, affording 4-substituted-2-methyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-
ones 6 and their ring opened products. However, no such rearrangement was observed with (6-





= N(CH3)2, indoline, morpholino, NHAr). As expected, 2-substituted-4-methyl-
6H-pyrimido[1,2-a][1,3,5]triazin-6-ones 4 were obtained as the final products. Experimental 
2 
 
structural determination and theoretical studies were carried out to get an understanding of the 
observed thermal rearrangement. In addition, an attempt to obtain similar pyrimido[1,2-
a][1,3,5]triazin-6-ones using N,N-dimethylacetamide dimethyl acetal (DMA-DMA) as one 
carbon inserting synthon had furnished triazine ring annulated product 14 bearing N,N-dimethyl 
enamino substituent at position 4 as a result of further reaction with a second molecule of DMA-
DMA. 
 




1,3,5-triazine nucleus is a prominent structural core present in numerous biologically active 
compounds. Hexamethylmelamine, irsogladine and 5-aza-2’-deoxycytidine, which are 














 have been reported to show anti-cancer properties. 
Moreover, numerous derivatives of pyrimidine fused systems such as pyrido[2,3-d]pyrimidine 
(PD-0332991)
7
 and pyrimido[1,2-a]pyrimidine (4)
8 
have also demonstrated promising anticancer 
properties as well. Due to the close structural similarity with the above pyrimido fused bicyclic 
scaffolds and reports on antiproliferative activity from 1,3,5-triazino fused heterocycles, the 
derivatives of pyrimido[1,2-a][1,3,5]triazine scaffold were anticipated to possess anticancer 
property (Fig. 1). To date, heterocyclic compounds possessing a pyrimido[1,2-a][1,3,5]triazine 
moiety have been reported to exhibit antimicrobial
9
, potent fungicidal and average serotoninergic 
3 
 
(5-HT1A and 5-HT1B receptor) activities
10
 as well as GSK-3β inhibitory activity with potential for 










































GI50 (A549) value = 15M
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Fig. 1 Structurally similar nitrogen containing heterocyclic scaffolds  
 
In the literature, synthetic access to pyrimido[1,2-a][1,3,5]triazine analogues (in which one of the 
four nitrogen atoms is located at the junction of the two cycles) is rather limited and most of the 
synthetic approaches described cannot provide the flexibility of different substitution at various 
positions around the fused rings. The synthesis of pyrimido[1,2-a][1,3,5]triazine system
12
 can be 
categorized into two approaches: (1) annulation of pyrimidine onto a 1,3,5-triazine scaffold
13
; (2) 
annulation of the 1,3,5-triazine ring onto a pyrimidine scaffold
14
. The latter approach has been 
4 
 
largely adopted for the preparation of pyrimido[1,2-a][1,3,5]triazines and most authors largely 
focussed on the formation of dioxo/dithio/oxothiooxo derivatives of the scaffold
14g-p
. Therefore, 
there is a need to find more practical approaches for the synthesis of these pyrimido[1,2-
a][1,3,5]triazines. 
Since orthoesters are versatile one-carbon building blocks in ring annulation reactions, it was 
expected that unsymmetrically substituted pyrimidin-2-yl guanidine 3 (acting as a penta atomic 
synthon) would react with this one-carbon building block to yield, theoretically, either one of the 
regioisomeric pyrimido[1,2-a][1,3,5]triazin-6-ones 4 or 5 or both as product/s. However, the 
possibility of structure 5 was excluded, as no cross-peaks were found between the R
3
 group 
protons of pyrimidine ring and methyl group protons of triazine ring in 2D NOESY experiment 
(Scheme 1). Moreover, according to DFT calculations in gas phase, the structure 5 was found to 
be highly unfavourable energetically (vide infra). In addition, a regioisomeric product similar to 4 
was observed exclusively when other one-carbon inserting synthon like aldehyde was used with 
similar substrate
15
. However, to our surprise, product 4 (Table 1) was found readily rearranged in-
situ to a thermodynamically more favourable product of type 6 and its ring-opened product 6’ 




 group present in the starting material guanidine (Table 
2). Herein, the details of this unexpected thermal rearrangement are presented.  
 
Results and Discussion 
The starting material N-(4-substituted-6-oxo-1,6-dihydropyrimidin-2-yl)guanidines, 3,
 
were 
prepared either by method A or B (Scheme 1). In method A, 3 was synthesized via microwave 
(MW) assisted nucleophilic addition of amines onto (4-methyl-6-oxo-1,6-dihydropyrimidin-2-
yl)cyanamide 1 using either concentrated hydrochloric acid or trimethyl silyl chloride (TMSCl) 
5 
 
catalyzed conditions; whereas in method B, cyclocondensation of β-keto ester with substituted 
biguanides 2 yielded 3 as reported by Curd and Rose
16
 (Scheme 1). Method A was found to be 
more versatile and robust for molecular library generation. In the presence of protic acid (method 
A procedure 1) or TMSCl (method A procedure 2) catalyzed conditions, the reaction times were 
shorter, workup was easy obviating the need of column chromatography and appreciable yields of 
3 (56-93%) were obtained with a variety of primary and secondary amines with alkyl, aryl and 
aralkyl substituents. In the latter case (i.e. method A procedure 2), TMSCl not only acted as a 























































Scheme 1. Reagents and Conditions: (i) ethyl 3-oxobutanoate/ ethyl 4,4,4-trifluoro-3-






































































































































































































































































- HCl - SiHMe3
1 3  
Scheme 2. Synthesis of 1,6 dihydropyrimidinyl guanidines 3 under TMSCl catalyzed conditions 
 
The structures of the products were deduced from their mass spectra, NMR data and elemental 
analyses. The reactions were carefully monitored using TLC and the reactions were stopped 
immediately when no trace of the starting material was observed. The reaction proceeded only 
on heating at 100°C. The reaction between these guanidines (3) and triethyl orthoacetate (in 
presence of glacial acetic acid) yielded product 4 predominantly when the guanidine 3 contained 




= N(CH3)2, -N(CH2CH2)2O, indolino). Similarly when an 




= NHPh, NHPh(3-Br), 
NHPh(3-Cl), NHPh(4-OMe)), the predominant compound was 4. Product 4 was characterized by 
9 
 
the diagnostic methyl peak of the triazine ring at δ2.85-2.91 in 
1
H NMR and 26.2-27.8 in 
13
C 
NMR as well as X-ray crystallography of 4i (Fig. 2; please refer to supporting information for 
structural details). However, upfield shift to δ2.18-2.29 in 
1
H NMR and 25.2-25.6 in 
13
C NMR 
were observed, surprisingly, in isolated products when unsubstituted (3a), alkylsubstituted (3b) 
or aralkyl guanidines (3g, 3h) were used as a substrate under similar conditions. Therefore, the 
product obtained from reactants 3a, 3b, 3c, 3g and 3h was expected to have a structure different 
from 4 even though the mass spectra showed expected values corresponding to structure 4. 
Hence, to confirm this aspect, X-ray crystallographic study of the product obtained from 3a was 
performed.  
 
Figure 2. X-ray crystal structure of 2-(dimethylamino)-4,8-dimethyl-6H-pyrimido[1,2-
a][1,3,5]triazin-6-one 4i (displacement ellipsoids are drawn at 50% probability level) CCDC 
791289 
 
The fact that there were clearly differentiated chemical shifts at δ 10.18 and 9.26 for the product 
obtained by the reaction of triethyl orthoacetate with 3a in the 
1
H NMR spectrum supported the 
existence of hydrogen bonding between the peri-carbonyl and the proximate exocyclic N-H 
which is not possible in structure 4. Moreover, similar lowfield shifts of NH proton in 
1
H NMR 
from 10.18-13.20 ppm were observed in 6b-c and 6g-h. X-ray crystallographic study
17
 of this 
10 
 
product (Figure 3) revealed that the product 4a (not isolated) underwent a smooth rearrangement 
to an isomeric product 6a in-situ as suspected from NMR studies. So, structure 6 was assigned to 
the rearranged product with upfield shift, in the cases of 3a, 3b, 3c, 3g and 3h. Moreover, NMR 
studies were found to be consistent with the X-ray crystallographic data of 6a (Figure 3) where 
hydrogens attached to N5 have unequal bond lengths and the amino group was found to be 
locked in the plane of pyrimido[1,2-a][1,3,5]triazine nucleus due to the π-electron delocalization 
with the heterocycle.  
 
Figure 3. X-ray crystal structure of 4-amino-2,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-
one 6a CCDC 788427  
The proposed mechanism for the formation of rearranged product 6 is depicted in Scheme 3. The 
reaction starts with the exchange of alkoxy groups of the orthoester (in excess) under acid 
catalysis, which then reacted with the guanidine 3 (nucleophile) to give iminium ion intermediate 
7. Subsequent loss of EtOH gave 4. Thermal rearrangement is then assumed to proceed at around 




 = H) according to scheme 3. 
The mechanism may have involved: a) acid catalyzed ethanolytic ring opening of pyrimidine at 
amide linkage with the formation of ring open triazine carbenone 6’ (acrylic acids were isolated); 
b) intramolecular nucleophilic attack by N-1 nitrogen of 1,3,5-triazine on the carbonyl group and 
subsequent ring closure that gave final product 6. It is worth mentioning that the thermally 
11 
 
assisted rearrangement of 4-amino-8-methylpyrimido[1,2-a][1,3,5]triazin-6-one 8 to 4-amino-6-
methylpyrimido[1,2-a][1,3,5]triazin-6-one 10 was reported
14b
 to have resulted from 1,3,5-
triazine ring opening via carbodiimide intermediate 9 (Scheme 4). However, the rearrangement 
involving pyrimidine ring opening similar to the one proposed in scheme 3 (depicted using 
hashed arrows in scheme 4) leading to product 12 via ketene intermediate 11 could not be 
avoided. Moreover, careful analysis of the provided 
1
H NMR spectral data seems to corroborate 
structure 12 (2-amino-8-methylpyrimido[1,2-a][1,3,5]triazin-6-one) as ~1.2 ppm downfield shift 
of the methine proton (in blue) signal on the triazine ring after the rearrangement can only be 




























































































Scheme 4. Alternate plausible mechanism for the rearrangement in pyrimido[1,2-
a][1,3,5]triazin-6-ones via pyrimidine ring opening leading to regioisomeric product 12 instead 
of proposed 10. 
 
Intramolecular hydrogen bonding between the 4-amino hydrogen and carbonyl oxygen (Figure 
3) as well as involvement of amino group (directly attached to the ring) in π-electron 
delocalization with the pyrimido[1,2-a][1,3,5]triazin-6-one nucleus provides additional stability 
to the rearranged product 6 which might provide the driving force for such a rearrangement. 
Therefore, an attempt was made to assess the relative stability of the two possible 









=Me) using Gaussian 03 software package
18
. Regioisomer 5 was also included in the 
study as the similar cyclization of benzimidazol-2-yl guanidines (unsymmetrically substituted in 
the phenylene fragment) with one carbon inserting reagents did not proceed regioselectively in 
one of our previous works
3
. The results of these calculations are presented in Table 2. 
Rearranged product 6a was found to be energetically more favourable than 4a whereas 4i was 
found to be more favourable over 6i (Table 2). This was found to be in agreement with the 
13 
 
experimental observation. Theoretical calculations at B3LYP/6-311G 2d,2p// B3LYP/6-311G 
d,p explained the formation of exclusively one regioisomeric product as both 5a and 5i were 
highly energetically unfavourable (might be due to steric factors). 
Table 2 Relative energies according to ab-initio calculations  
 Relative energies, kcal/mol 










=CH3 0.00 17.65 8.72 
 
In an attempt to obtain similar pyrimido[1,2-a][1,3,5]triazin-6-ones, the reaction of 3i with 
another one carbon electrophilic synthon-DMA-DMA 13 (N,N-dimethylacetamide dimethyl 
acetal) yielded a product having m/z 288.3 (Scheme 5). The product formation started after 1 
hour and completed in 2.5-3h. The 
1
H NMR and 
13
C spectra of the compound had two sets of 
NMe2 signals at 3.10 and 3.15 as well as 37.1 and 37.3 ppm respectively. Based on the above 
observations, results of DEPT experiment, as well as the 2D NOESY crosspeaks, it was 
suggested that a second molecule of DMA-DMA could have contributed to the =C(CH3)-NMe2 
fragment, although the stereochemistry around the double bond in the enamine substituent at 
position 4 could be E or Z. The structure 14, a new heterocyclic pyrimido[1,2-a][1,3,5]triazin-6-
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Scheme 5 
 
Figure 4 X-ray crystal structure of (E)-2-(dimethylamino)-4-(2-(dimethylamino)prop-1-enyl)-8-
methyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one 14 (displacement ellipsoids are drawn at 50% 
probability level), CCDC 838638
 
A reaction mechanism for the formation of the product is proposed in scheme 6. The mechanism 
of formation of 1,3,5-triazine 14 can be rationalized through the reaction with an iminium ion 
MeC(OMe)=
+
NMe2 derived from 13 to form the required enamine 15; this is followed by 
cyclisation and tautomerization with the loss of HNMe2 to give 4i and subsequent reaction with 




Scheme 6. Mechanistic rationale for the formation of 14 
The comparison of bond lengths obtained from X-ray crystal structures of three pyrimido[1,2-
a][1,3,5]triazin-6-ones 6a, 4i and 14 revealed interesting findings (Table III, supporting 
information). The C4 N3 bond length (C5 N4 according to crystallographic numbering) in 
triazine ring of 4i was found to be unusually short (1.289Å) suggesting higher order of double 
bond character whereas C4 N5 bond length (C6 N1 according to crystallographic 
numbering) of 14 was unusually large suggesting more sp
3
 character of bridge head nitrogen. The 
pyrimidine and 1,3,5-triazine rings were found to be coplanar for both 6a and 4i in the crystal 
structures as well as in their optimized geometries obtained from DFT calculations (vide infra). 
However, C=O of pyrimidine ring bent downwards while position 4 enamine side chain of 
triazine ring is twisted upwards (torsional angle C1-N1-C6-N3 = 20.6°) increasing O  ּ  ּ  ּ C10 
bond distance in 14 to 2.762 Å compared to O  ּ  ּ  ּ C8 bond distance which is 2.64 Å. 
Stereochemistry of the enamine fragment at position 4 was found to be E.  
Next, the antiproliferative activity of the synthesized compounds was assessed using MTT 
assay
19
. In particular, lung A549 and MDA-MB-231 breast cancer cell lines were used. No 
16 
 
appreciable antiproliferative activity was obtained for all the synthesized compounds except for 
2-(3-chlorophenylamino)-4,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (4e) which 
demonstrated IC50 value of 37.5±2.8 μM and 51.2±3.5 μM for A549 and MDA-MB231 cell line 
respectively.  
Conclusion 
In summary, the reactions of N-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidines with 
triethyl orthoacetate were investigated. 2-amino-4-methylpyrimido[1,2-a][1,3,5]triazin-6-ones 4 
and the products of unexpected rearrangement, namely 4-amino-2-methylpyrimido[1,2-
a][1,3,5]triazin-6-ones 6, were obtained depending upon the starting guanidine. The 
rearrangement involved opening of the pyrimidine ring as was shown by isolation of acrylic acid 
intermediates. The requirements for the rearrangement were discussed on the basis of results 
obtained from experimental and theoretical studies. This approach opened the opportunities to 
insert different substituents at position 2 and position 4 of triazine ring, depending upon the 
starting guanidine. The attempt to obtain similar pyrimido[1,2-a][1,3,5]triazin-6-ones using 
DMA-DMA was unsuccessful, as unexpected cyclocondensation product 14 formed as a result 




Melting points (uncorrected) were determined on a Gallenkamp melting point apparatus. NMR 
spectra were recorded on a Bruker DPX-300 spectrometer using Me2SO-d6 as a solvent and TMS 
as an internal reference. IR spectra were performed on a Perkin Elmer Spectrum 100 FT-IR 
spectrophotometer in potassium bromide pellets. Mass spectra were obtained on a Shimadzu 
17 
 
LCMS-IT-TOF system using electron spray ionization (ESI) mode. The course of the reactions 
was monitored by TLC on Silica gel 60 F254 plates (Merck, Germany). HPLC analysis was 
performed on an Agilent Eclipse XDB-C18 (4.6x250 mm, 5 μm) column at 30ºC, with a flow 
rate of 1mL/min. 5-90% Gradients of MeOH/MeCN (solvent A) and H2O (solvent B) were used 
as mobile phases. Microwave reactions were conducted using a commercially available 
monomode microwave unit (CEM Discover). Elemental analyses were performed on the Perkin 
Elmer 2400 Elemental Analyzer Series II.  
Crystal structure determinations: The single-crystal X-ray diffraction study was carried out on a 
Bruker APEX diffractometer attached to a CCD detector and graphite-monochromated MoKα 
radiation (λ, 0.71073 Å) using a sealed tube. Absorption corrections were made with the program 
SADABS
20
 and the crystallographic package SHELXTL
21
 was used for all calculations. 
General method for the preparation of 3a-j  
Method A Procedure 1: Into a 5 mL microwave vessel was added N-(4-substituted-6-oxo-1,6-
dihydropyrimidin-2-yl)cyanamide (2 mmol) followed by amine hydrochloride (2.12 mmol) and 
isopropanol/ACN (1.0 ml). The vial was sealed and the mixture was irradiated at 160-170
°
C for 
15 min and allowed to cool. The white solid obtained was filtered, washed with solution of 
sodium hydrogen carbonate and cold water and dried. 
Procedure 2: Into a 5 mL microwave vessel was added N-(4-substituted-6-oxo-1,6-
dihydropyrimidin-2-yl)cyanamide (2 mmol), amine (2.1 mmol) followed by the slow addition of 
a 2 N solution of TMSCl (1.04 mL, 2.1 mmol, 1.1 equiv) in CH3CN under cold conditions. After 
the vial was capped, reaction mixture was irradiated for 12 min at 160 °C. After the mixture was 
cooled to approximately 60°C, iPrOH (0.55mL, 6 mmol, 3.0 equiv) was added. The mixture was 
stirred for 10 s and then irradiated a second time at 125°C for 30 s. Upon cooling, the 
18 
 
hydrochloride salts of guanidines 3 precipitated, and it was collected, washed with cold CH3CN 
and then with solution of sodium hydrogen carbonate and cold water and finally dried to obtain 
slightly better yields of pyrimidinyl guanidines. 
Method B: Biguanides were synthesized according to Uohama et al
22
 and subsequent pyrimidine 
ring annulation was done using
 
method described by Curd and Rose
16
. 
Experimental data for some representative compounds: 





H NMR (300 MHz, Me2SO-d6): δ 2.08 (3H, s, Me), 5.58 (1H, s, H-
5), 8.03 (4H, br. s, guanidino NHs), 11.52 (1H, br. s, NH); 
13
C NMR (75 MHz, Me2SO-d6): δ 
23.2 (Me), 103.0 (CH), 158.5, 159.8, 163.0 (br. s), 166.9 (br. s). 
1-(6-oxo-4-phenyl-1,6-dihydropyrimidin-2-yl)guanidine (3b). Yield: 37%; Method B (using 
NaOMe instead of aq NaOH in second step); mp 273°C (decomposed); lit
24
 mp 273°C; LC-MS 




H NMR (300 MHz, DMSO-d6): d 6.24 (1H, s, CH), 7.87 (2H, d, J = 
7.9 Hz, H-2’ and H-6’), 7.38–7.49 (3H, m, H-3’, H-4’ and H-5’), 8.27 (4H, br. s, NHC(=NH)NH2), 
11.53 (1H, s, NH). 
N-methyl-N’-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3c). Yield 62%; Method A 
(procedure 1/2); mp 272-273
°
C; TLC (silica gel, MeOH:CH2Cl2, 1:6): Rf 0.38. 
1
H NMR (300 MHz, 
DMSO-d6): δ 2.03 (3H, s, CH3), 2.75 (3H, d, 
3
J = 4.5 Hz, NCH3), 5.49 (1H, s, H-5), 7.96-9.20 (3H, 
br. s, NH-C(=NH) NH), 10.86 (1H, br. s, NH).  
1-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-3-phenylguanidine (3d). Yield 90%; Method A 




 mp 244-246°C; 
1
H NMR (300 MHz, Me2SO-
d6): δ 2.09 (3H, s, Me), 5.60 (1H, s, CH), 7.00 (1H, t, J = 7.2 Hz, H-4’), 7.26 (2H, t, J = 7.5 Hz, 
19 
 
H-3’ and H-5’), 7.66 (2H, d, J = 7.5 Hz, H-2’ and H-6’), 8.12 (2H, br. s., NH-C(=NH)N), 9.04 
(1H, s, NH), 11.18 (1H, s, NH);
 13
C NMR (75 MHz, Me2SO-d6): 23.5 (Me), 103.7 (C-6), 120.3, 
122.3, 128.6, 138.9, 155.9, 158.3, 163.0, 163.7. 
1-(3-chlorophenyl)-3-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3e). Yield 90%; 




H NMR (300 MHz, 
DMSO-d6): δ 2.10 (s, 3H, CH3), 5.62 (s, 1H, CH), 7.02 (dd, 1H, J = 7.9 Hz, 1.2 Hz, H-4’), 7.26 
(t, 1H, J = 8.1 Hz, H-5’), 7.63 (d, 1H, J = 7.9 Hz, H-6’), 7.75 (s, 1H, H-2’), 8.24 (br. s., 2H, ), 
9.10 (s, 1H, NH), 11.43 (s, 1H, NH);
 13
C NMR (75 MHz, DMSO-d6): 26.7 (CH3), 107.4 (C-5), 
121.8, 122.5, 125.2, 133.4, 136.3, 144.0 (C-1’), 158.9, 161.5, 166.2, 167.0.  
1-(4-methoxyphenyl)-3-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3f). Yield 




H NMR (300 
MHz, Me2SO-d6): δ 2.01 (3H, s, Me), 3.72 (3H, s, OMe), 4.35 (2H, d, J = 4.9 Hz, CH2), 5.46 
(1H, s, CH), 6.89 (2H, d, J = 8.3 Hz, H-3’ and H-5’), 7.28 (2H, d, J = 8.7 Hz, H-2’ and H-6’), 
7.82 (2H, br. s., NH-C(=NH)N), 10.67 (1H, s, NH). 
1-(4-chlorobenzyl)-3-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3g). Yield 68%; 




H NMR (300 MHz, Me2SO-d6): δ 2.04 (3H, s, Me), 5.22 (2H, s, 
CH2), 5.60 (1H, s, H-5), 7.14 (2H, br. s, NH-C(=NH)N), 7.33 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 
7.47 (2H, d, J = 8.7 Hz, H-2’ and H-6’), 10.71 (1H, br. s, NH); 
13
C NMR (75 MHz, Me2SO-d6): δ 
23.4 (Me), 42.7 (CH2), 101.3 (C-5), 127.8 (C3’ and C-5’), 130.0 (C-2’ and C-4’), 131.1 (C-1’), 
137.7 (C-4’), 157.5 (C-2), 159.7 (C-4), 161.0, 162.6. 
N,N-dimethyl-N’-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)guanidine (3i). Yield 59%; 
Method A (procedure 1/2) or Method B; mp 227-228
°
C; TLC (silica gel, MeOH:CH2Cl2, 1:6): Rf 
0.57. 
1
H NMR (300 MHz, DMSO-d6): δ 2.03 (3H, s, CH3), 2.97 (6H, s, N(CH3)2), 5.45 (1H, s, H-
20 
 
5), 8.46 (2H, br. s, NH-C(=NH)N), 10.58 (1H, br. s, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 23.6 
(CH3), 36.4 (N(CH3)2), 102.2 (C-5), 157.9 (C-2), 158.3 (C-4), 162.9 (C=NH), 163.7 (C=O).  
N-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)morpholine-4-carboxamidine (3j). Yield 36%; 







(300 MHz, Me2SO-d6): δ 2.03 (3H, s, Me), 2.75 (3H, d, 
3
J = 4.5 Hz, N Me), 5.49 (1H, s, H-5), 
7.96-9.20 (3H, br. s, NH-C(=NH) NH), 10.86 (1H, br. s, NH). 
N-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)indoline-1-carboxamidine (3k). Yield 61%; 




H NMR (300 MHz, DMSO-d6): δ 2.10 (3H, s, CH3), 
3.15 (2H, t, 
3
J = 8.5 Hz, CH2), 3.97 (2H, t, 
3
J = 8.5 Hz, CH2), 6.93 (1H, t, 
3
J = 7.2 Hz), 7.09 (1H, 
t, 
3
J = 7.7 Hz), 7.17 (1H, d,
 3
J = 7.2 Hz), 8.64 (1H, d,
 3
J = 8.3 Hz), 11.24 (1H, s, NH). 
13
C NMR 
(75 MHz, DMSO-d6): δ 23.5 (CH3), 26.4 (3’-CH2), 47.3 (2’-CH2), 103.5 (C-5), 118.1, 122.1, 
124.1, 126.9, 131.6, 142.4, 157.9 (C-2), 155.3 (C-4), 162.7 (C=NH), 163.7 (C=O). 
1-(3-bromophenyl)-3-(6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-2-yl)guanidine (3l). 
Yield 70%; mp 161-162°C (EtOH); 
1
H NMR (300 MHz, Me2SO-d6): δ 6.18 (1H, s, H-7), 7.12-
7.28 (2H, m, HAr), 7.74-7.89 (2H, m, HAr), 8.32 (1H, br. s., NH), 10.19 (1H, br. s., NH), 12.05 
(1H, br. s., NH); 
13
C NMR (75 MHz, Me2SO-d6): δ 103.4 (q, 
3
JC-F = 3.1 Hz, C-7), 119.1, 120.9 
(q,
1
JC-F = 274.4 Hz, CF3), 121.4, 121.9, 122.8, 125.0, 130.4, 140.8, 150.9 (q, 
2
JC-F = 33.3 Hz, C-
8), 156.2, 159.5, 163.4 
N-(4-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)cyanamide (1).  




 mp >300 
°
C; TLC (silica gel, MeOH:CH2Cl2, 1:6): Rf 0.43. 
1
H 
NMR (300 MHz, Me2SO-d6): δ 1.93 (3H, s, Me), 5.20 (1H, s, C-5), 10.22 (1H, s, NH); 
13
C NMR 





General method for the preparation of 8(2)substituted 4(8)-methylpyrimido[1,2-a][1,3,5] triazin-
6(4)-ones 4 or 6: 
Guanidines (3a-j), 0.25 ml acetic acid and excess triethylorthoacetate were refluxed under 
nitrogen atmosphere for 0.3-9h. Solvent was evaporated to dryness on rotary evaporator, purified 
using column chromatography and finally recrystallised using suitable solvent. 
4,8-dimethyl-2-(phenylamino)-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (4d). mp 220-221°C 





Calcd. for C14H13N5O: C, 62.91; H, 4.90; N, 26.20; Found 62.61, 4.95, 26.03. 
1
H NMR (300 
MHz, Me2SO-d6): δ 2.18 (3H, s, 8-Me), 2.90 (3H, s, 4-Me), 5.92 (1H, s, H-7), 7.13 (1H, t, 
3
J = 
7.4 Hz, H-5’), 7.38 (2H, t, 
3
J = 7.7 Hz, H-3’ and H-5’), 7.86 (2H, d, 
3
J = 7.5 Hz, H-2’ and H-6’), 
10.63 (1H, s, NH); 
13
C NMR (75 MHz, Me2SO-d6): δ 23.7 (2-Me), 26.2 (8-Me), 103.6 (C-5), 
120.4 (C-2’ and C-6’), 123.9 (C-4’), 128.6 (C-3’ and C-5’), 138.0 (C-1’), 152.9, 156.8 (C-2), 
160.0, 163.8, 166.7; IR (KBr); v 3109 br NH, 1685 C=O, 1627, 1535, 1244, 1036, 821, 752.  
 
2-(3-chlorophenylamino)-4,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (4e). mp 239-




Anal. Calcd. for C14H12ClN5O: C, 55.73; H, 4.01; Cl, 11.75; N, 23.21; Found: C, 55.49; H, 4.05; 
Cl 11.50; N, 22.98. 
1
H NMR (300 MHz, Me2SO-d6): δ 2.19 (1H, s, 8-Me), 2.91 (1H, s, 4-Me), 
5.96 (1H, s, H-7), 7.18 (1H, d, J = 8.3 Hz, H-4’), 7.40 (1H, t, J = 8.1 Hz, H-5’), 7.76 (1H, d, J = 
7.9 Hz, H-6’), 8.06 (1H, s, H-2’), 10.79 (1H, s, NH); 
13
C NMR (75 MHz, Me2SO-d6): 23.8 (8-
Me), 26.2 (4-Me), 104.0 (C-7), 118.7, 119.5, 123.5, 130.3, 133.0, 139.7 (C-1’), 152.7, 156.9, 





2-(4-methoxyphenylamino)-4,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (4f). mp 





Anal. Calcd. for C15H15N5O2: C, 60.60; H, 5.09; N, 23.56. Found: C, 60.47; H, 5.10; N, 
23.29. 
1
H NMR (300 MHz, Me2SO-d6): δ 2.16 (3H, s, 8-Me), 2.88 (3H, s, 4-Me), 3.75 (3H, s, 
OMe), 5.89 (1H, s, H-7), 6.96 (2H, d, J = 8.8 Hz, H-3’ and H-5’), 7.74 (2H, d, J = 8.8 Hz, H-2’ 
and H-6’), 10.52 (1H, s, NH); 
13
C NMR (75 MHz, Me2SO-d6): 23.7 (4-Me), 26.2 (8-Me), 55.2 
(OMe), 103.2 (C-7), 113.8 (C-2’ and C-6’), 122.1 (C-3’ and C-5’), 130.9 (C-1’), 153.1 (C-4’), 
155.8, 156.5, 160.1, 163.5, 166.7; IR (KBr); v 3109, 2920 (CH), 2850, 1670 C=O, 1627, 1541, 
1419, 1236, 1174, 1028, 831, 788.  
2-(dimethylamino)-4,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (4i). mp 190-191°C 




Anal. Calcd for 
C10H13N5O: C, 54.78; H, 5.98; N, 31.94; found: C, 54.42; H, 5.87; N, 31.69. 
1
H NMR (300 MHz, 
Me2SO-d6): δ 2.12 (3H, s, 8-Me), 2.85 (3H, s, 4-Me), 3.14 (3H, s, N(Me)2), 3.25 (3H, s, N(Me)2), 
5.78 (1H, s, H-7); 
13
C NMR (75 MHz, Me2SO-d6): δ 23.8 (8-Me), 26.6 (4-Me), 36.3 (N(Me)2, 
36.4 (N(Me)2, 101.8 (C-7), 153.1, 158.0, 160.1, 163.5, 167.2 (C=O). ; IR (KBr); v 3420 br NH, 
3034 (CH), 2978, 1714, 1670 C=O, 1620, 1516, 1317, 1238, 1192, 1078, 1033, 966, 825, 794, 
717. 
4,8-dimethyl-2-morpholino-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (4j). mp 191-192°C; TLC 




Anal. Calcd for C12H15N5O2: C, 
55.16; H, 5.79; N, 26.80; found C, 55.22; H, 5.77; N, 26.86. 
1
H NMR (300 MHz, Me2SO-d6): δ 
2.13 (3H, s, 8-Me), 2.86 (3H, s, 4-Me), 3.67 (t, J = 4.5 Hz, 4H, (CH2)2O), 3.78 (t, J = 4.3 Hz, 2H, 
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N(CH2), 3.89 (t, J = 4.3 Hz, 2H, N(CH2), 5.81 (s, 1H, H-7); 
13
C NMR (75 MHz, Me2SO-d6): δ 
25.0 (8-Me), 27.8 (4-Me), 44.8 (CH2), 45.3 (CH2), 66.7 (CH2), 67.1 (CH2), 103.3 (C-7), 154.4, 
158.3, 161.2, 165.5, 168.3 (C=O); IR (KBr); v 3388 br NH, 3076 (CH), 2950, 1627 C=O, 1543, 
1508, 1406, 1352, 1246, 1181, 1028, 966, 834. 
2-(indolin-1-yl)-4,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (4k). mp 212-213°C 
(AcOEt);
 
TLC (silica gel, 9:1 AcOEt:Hex): Rf 0.32; Anal. Calcd for C16H15N5O: C, 65.52; H, 
5.15; N, 23.88; found C, 65.27; H, 5.14; N, 23.74. 
1
H NMR (300 MHz, Me2SO-d6): δ 2.18 (3H, s, 
8-Me) and 2.21 (3H, s, 8-Me), 2.94 (3H, s, 4-Me) and 3.00 (3H, s, 4-Me), 3.20 (2H, t, 
3
J = 8.5 
Hz, 3’CH2), 4.19 (1H, t, 
3
J = 8.3 Hz, CH2) and 4.32 (1H, t, 
3
J = 8.9 Hz, CH2), 5.92 (2H, s, CH), 
6.98-7.16 (2H, m, H-4’), 7.21-7.40 (4H, m, H-5’ and H-6’), 8.29 (1H, d,
 3
J = 8.2 Hz, H-7’), 8.49 
(1H, d,
 3
J = 8.1 Hz, H-7’); 
13
C NMR (75 MHz, Me2SO-d6): δ 23.5 (Me), 26.4 (3’-CH2), 47.3 (2’-
CH2), 103.5 (C-5), 118.1, 122.1, 124.1, 126.9, 131.6, 142.4, 157.9 (C-2), 155.3 (C-4), 162.7 
(C=NH), 163.7 (C=O). IR (KBr); v 3446 br NH, 2935 (CH), 2918, 2854, 1707 C=O, 1624, 1576, 
1481, 1456, 1249, 1195, 785.1. 
2-(3-bromophenylamino)-4-methyl-8-(trifluoromethyl)-6H-pyrimido[1,2-a][1,3,5]triazin-6-
one (4l). Yield: 70%; mp 216-217°C (EtOH); TLC (silica gel, 9:1 AcOEt:Hex): Rf 0.90. 
1
H NMR 
(300 MHz, Me2SO-d6): δ 2.91 (1H, s, Me), 6.54 (1H, s, H-7), 7.32-7.42 (2H, m, H-4’ and H-5’), 
7.86 (1H, d, 
3
J = 6.8 Hz, H-6’), 8.10 (1H, s, H-2’), 11.08 (1H, s, NH); 26.07 (CH3), (C-4), 103.3 
(q, 
3
JC-F = 2.6 Hz, C-7), 119.5, 120.6 (q,
1
JC-F = 275.4 Hz, CF3), 121.5, 122.8, 127.1, 130.8, 139.2, 
152.6 (q, 
2
JC-F = 34.0 Hz, C-8), 155.1, 157.2, 160.2, 164.4; IR (KBr); v 3282 NH, 3081, 2945, 
1699 C=O, 1631, 1608, 1587, 1552, 1465, 1375, 1340, 1278, 1192, 1155, 1101, 1083, 925, 875, 
788, 707; % purity >95% tR = 7.1 min. 
4-amino-2,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (6a). mp 264-265°C; TLC 
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Anal. Calcd for C8H9N5O: C, 
50.26; H, 4.74; N, 36.63; found: C, 50.35, H, 4.95, N, 36.03.
1
H NMR (300 MHz, Me2SO-d6): δ 
2.18 (1H, s, 2-Me), 2.24 (1H, s, 8-Me), 6.04 (1H, s, H-7), 9.26 (1H, s, NH), 10.18 (1H, s, NH); 
13
C NMR (75 MHz, Me2SO-d6): 23.8 (8-Me), 25.2 (2-Me), 104.6 (C-7), 152.9, 156.8, 162.7, 
167.6, 172.7; IR (KBr); v 3294 NH, 3116 br, 1695 C=O, 1647, 1575, 1400, 1197, 1170, 1060, 
821, 792, 748, 702. 
4-amino-2-methyl-8-phenyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (6b). Yield: 58%; mp 
258-259°C (80AcOEt:20Hex); TLC (silica gel, 9:1 AcOEt:Hex): Rf 0.45;. 
1
H NMR (300 MHz, 
Me2SO-d6): δ 2.29 (1H, s, 2-CH3), 6.77 (1H, s, H-7), 7.44-7.61 (3H, m, H-3’, H-4’, H-5’), 8.12 
(2H, d, J = 8.1 Hz, H-2’ and H-6’), 9.32 (1H, s, NH), 10.22 (1H, s, NH); 
13
C NMR (75 MHz, 
Me2SO-d6): 25.2 (2-CH3), 101.2 (C-7), 127.1, 128.6, 131.1, 135.6 (C-1’), 153.4, 156.8, 162.3, 
163.6, 172.9; IR (KBr); v 3344 NH, 3213, 1674 C=O, 1624, 1570, 1544, 1448, 1382, 1220, 1174, 
908, 778; % purity >95%; tR 8.9 min 
2,8-dimethyl-4-(methylamino)-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (6c). mp 166-167°C 





Calcd. for C9H11N5O: C, 52.67; H, 5.40; N, 34.13; found: C, 52.49, H, 5.69, N, 32.83. 
1
H NMR 
(300 MHz, Me2SO-d6): δ 2.18 (3H, s, 2-Me), 2.28 (3H, s, 8-Me), 2.98 (3H, d, J = 4.9 Hz, NMe), 
6.07 (1H, s, H-7), 10.90 (1H, d, J = 4.5 Hz, NH); 
13
C NMR (75 MHz, Me2SO-d6): 23.7 (8-Me), 
25.6 (2-Me), 28.4 (NMe), 104.8 (C-7), 152.6, 155.5, 163.0, 167.5, 172.3; IR (KBr); v 3324 NH, 
3201, 1690 C=O, 1642, 1574, 1440, 1187, 1165, 1065, 793, 774. 
4-(4-chlorobenzylamino)-2,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (6g). mp 133-










H NMR (300 MHz, Me2SO-d6): δ 2.19 (3H, s , 8-Me), 2.25 (3H, s, 2-Me), 4.69 (2H, s, 
CH2), 6.08 (1H, s, H-7), 7.39 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 7.43 (2H, d, J = 8.7 Hz, H-2’ 
and H-6’), 11.43 (1H, br. s., NH); 
13
C NMR (75 MHz, Me2SO-d6): 23.8 (2-Me), 25.6 (8-Me), 
43.9 (CH2), 105.0 (C-7), 128.3 (C-3’and C-5’), 129.5 (C-2’ and C-6’), 131.8 (C-4’), 136.4 (C-1’), 
152.7, 155.2, 163.2, 167.6, 172.3. ; IR (KBr); v 3170 br NH, 1689 C=O, 1618, 1411, 1377, 1344, 
827, 794, 711. 
4-(4-methoxybenzylamino)-2,8-dimethyl-6H-pyrimido[1,2-a][1,3,5]triazin-6-one (6h). mp 
138-139°C; TLC (silica gel, 9:1 AcOEt:Hex): Rf 0.26; LC–MS (ESI) m/z 312.1409 (MH
+
); Anal. 
Calcd. for C16H17N5O2: C, 61.72; H, 5.50; N, 22.49; found: C, 61.78; H, 5.42; N, 22.52. 
1
H NMR 
(300 MHz, Me2SO-d6): δ 2.19 (3H, s, 2-Me), 2.28 (3H, s, 8-Me), 3.74 (3H, s, OMe), 4.62 (2H, d, 
J = 5.7 Hz, CH2), 6.07 (1H, s, H-3), 6.91 (1H, d, J = 8.7 Hz, H-3’ and H-5’), 7.34 (1H, d, J = 8.3 
Hz, H-2’ and H-6’), 11.36 (1H, t, J = 5.7 Hz, NH); 
13
C NMR (75 MHz, Me2SO-d6): 23.8 (8-Me), 
25.6 (2-Me), 44.1 (CH2), 55.0 (OMe), 104.9 (C-7), 113.8 (C-2’ and C-6’), 128.9 (C-1’), 129.2 (C-
3’ and C-5’), 152.6 (C-4’), 155.1, 158.6, 163.3, 167.7, 172.4; IR (KBr); v 3109 br NH, 2950 
(CH), 1683 C=O, 1629, 1516, 1458, 1379, 1342, 1172, 1114, 1026, 821, 792. 
3-(6-methyl-4-(phenylamino)-1,3,5-triazin-2(1H)-ylideneamino)but-2-enoic acid (6’d). 
LC–MS (ESI) m/z 285.1293 (MH
+
); TLC (silica gel, 9:1 AcOEt:Hex): Rf 0.16; Anal. Calcd for 
C14H15N5O2: C, 58.94; H, 5.30; N, 24.55; found 56.18, H 4.89, N 23.58; 
1
H NMR (300 MHz, 
Me2SO-d6): δ 2.17 (3H, s, 8-Me), 2.25 (3H, s, 4-Me), 5.77 (1H, s, CH), 7.13 (1H, t, J = 7.3 Hz, 
H-4’), 7.33 (2H, t, J = 7.7 Hz, H-3’ and H-5’), 7.84 (2H, d, J = 7.9 Hz, H-2’ and H-6’), 10.94 
(1H, s, NHPh), 12.06 (1H, br s, NH), 13.75 (1H, br s, COOH).  
3-(4-(4-methoxyphenylamino)-6-methyl-1,3,5-triazin-2(1H)-ylideneamino)but-2-enoic acid 
(6’f). LC–MS (ESI) m/z 316.1255 (MH
+
); TLC (silica gel, 9:1 Hex:AcOEt): Rf 0.11; Anal. Calcd 
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for C15H17N5O3: C, 57.13; H, 5.43; N, 22.21; found C, 57.44; H, 5.21; N, 22.45.
 1
H NMR (300 
MHz, Me2SO-d6): δ 2.17 (3H, s, 8-Me), 2.24 (3H, s, 4-Me), 3.75 (3H, s, OMe), 5.74 (1H, s, CH), 
6.87 (2H, d, J = 8.3 Hz, H-2’and H-6’), 7.74 (2H, d, J = 9.0 Hz, H-3’and H-5’), 10.82 (1H, s, 




H NMR (300 MHz, Me2SO-d6): δ 2.12 (3H, s, 4-Me), 2.17 (3H, s, Me), 3.74 (3H, s, 
OMe), 4.57 (2H, d, J = 5.7 Hz, CH2), 5.66 (1H, s, H-3), 7.37 (2H, d, J = 8.7 Hz, H-3’ and H-5’), 
7.48 (1H, d, J = 8.3 Hz, H-2’ and H-6’), 9.30 (1H, t, J = 5.7 Hz, NH), 11.63 (1H, br s, NH), 13.72 
(1H, s, COOH). 
Western blot analysis  
Equal amounts of protein (50µg) in each lysate sample were separated by 10% sodium dodecyl 
sulfate (SDS)–polyacrylamide gel. Proteins were then electroblotted on nitrocellulose membranes 
and the blot was probed with a primary antibody followed by a secondary antibody (rabbit anti-




Appropriate guanidine and excess equivalent of DMA-DMA (with/without toluene) were 
refluxed under nitrogen atmosphere. The reaction was monitored using TLC. The solvent was 
evaporated to dryness on rotary evaporator, purified using column chromatography and finally 
recrystallized using suitable solvent. 
Yield: 73%; physical appearance: orange; mp 212-213°C (MeOH:AcOEt); MS (ESI) m/z: 289 
(MH
+




H NMR (300 MHz, Me2SO-d6): δ 2.06 (3H, s , 9-Me), 2.64 (3H, s, 4-Me), 3.05 (6H, s, (N(Me)2), 
3.05 (6H, s, (N(Me)2), 3.10 (6H, s, (NMe)2), 5.63 (1H, s, 8-CH), 6.13 (1H, s, =CH-N); 
13
C NMR 
(75 MHz, Me2SO-d6): 18.2 (4-Me), 23.6 (9-Me), 36.2 (N(Me)2), 36.4 (N(Me)2), 90.9 (=CH-N), 
101.1 (C-8), 154.7, 157.5, 158.4 (C-5), 157.5, 158.4, 161.3, 164.9, 166.1.  
(E)-4-(2-(dimethylamino)prop-1-enyl)-8-methyl-2-morpholino-6H-pyrimido[1,2-a] 
[1,3,5]triazin-6-one (14j). Yield: 69%; physical appearance: yellow; mp 217-218°C 
(MeOH:AcOEt); MS (ESI) m/z: 331 (MH
+
); Anal. calc. for C16H22N6O2: C, 58.17; H, 6.71; N, 
25.44; 
1
H NMR (300 MHz, Me2SO-d6): δ 2.06 (3H, s , 9-Me), 2.61 (3H, s, 4-Me), 3.11 (6H, s, 
(N(Me)2), 3.65 (4H, m, (CH2)2, 3.72 (4H, m, (CH2)2), 5.67 (1H, s, 8-CH), 6.17 (1H, s, =CH-N); 
13
C NMR (75 MHz, Me2SO-d6): 18.5 (4-Me), 23.5 (9-Me), 43.8 (O(CH2)2), 65.8 (N(CH2)2), 91.2 
(=CH-N), 101.5 (C-8), 154.8, 157.6, 158.0 (C-5), 161.2, 165.4, 165.9; IR (KBr); v 3352 br., 1681 
C=O, 1616, 1565, 1171, 979. 
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